The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Official Title: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Study ID: NCT03744676
Brief Summary: This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subjects will receive treatment with JCAR017 and will be followed for up to 2 years.
Detailed Description: This is an open-label, multicenter, Phase 2 study to assess the safety and antitumor activity in adult patients with relapsed or refractory B-cell non-Hodgkin Lymphoma when administered with lisocabtagene maraleucel (JCAR017) in the outpatient setting. Upon the successful product generation of lisocabtagene maraleucel, subjects will enter the treatment phase of the study. Treatment will include lymphodepleting chemotherapy followed by lisocabtagene maraleucel administration. Subjects will then enter the post-treatment follow-up phase of the study and will be followed for approximately 24 months for safety, disease status, health-related quality of life (HRQoL), and survival. Long-term follow-up will continue under a separate long-term follow-up protocol, per health regulatory authority guidelines, currently up to 15 years after the last lisocabtagene maraleucel administration.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Local Institution - 0057, Los Angeles, California, United States
Local Institution - 0060, Denver, Colorado, United States
Local Institution - 0089, Miami, Florida, United States
Local Institution - 0081, Orlando, Florida, United States
Local Institution - 0065, Indianapolis, Indiana, United States
Local Institution - 0069, Wichita, Kansas, United States
Local Institution - 0064, Louisville, Kentucky, United States
Local Institution - 0101, Southfield, Michigan, United States
Local Institution - 0052, East Brunswick, New Jersey, United States
Local Institution - 0066, Morristown, New Jersey, United States
Local Institution - 0041, Albany, New York, United States
Local Institution - 0039, Cincinnati, Ohio, United States
Local Institution - 0098, Eugene, Oregon, United States
Local Institution - 0051, Portland, Oregon, United States
Lancaster General Hospital, Lancaster, Pennsylvania, United States
Local Institution - 0037, Greenville, South Carolina, United States
Local Institution - 0063, Nashville, Tennessee, United States
Local Institution - 0097, Dallas, Texas, United States
Local Institution - 0061, San Antonio, Texas, United States
Baylor Scott and White Health, Temple, Texas, United States
Local Institution - 0096, Tyler, Texas, United States
Local Institution - 0074, Salt Lake City, Utah, United States
Local Institution - 0036, Norfolk, Virginia, United States
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR